Post by FireGene -

🔬 USP <85> vs USP <86>: The Future of Endotoxin Testing in Pharmaceutical QC The endotoxin testing landscape is undergoing a major transformation. While USP <85> (LAL/TAL-based BET) remains the long-established compendial standard, the introduction of USP <86> recombinant endotoxin testing methods marks a significant shift toward animal-free, sustainable, and biotech-driven analytical solutions. For QC and validation teams, this is not a replacement—but an expansion of capabilities. Key industry trends include: • Growing adoption of recombinant Factor C (rFC) technologies • Increased focus on sustainability and supply chain resilience • Rising validation complexity for biologics, cell & gene therapies • Continued regulatory expectation for USP <85> compliance alongside new alternatives In practice, most pharmaceutical manufacturers are moving toward a hybrid endotoxin testing strategy, combining traditional LAL/TAL methods with emerging recombinant platforms—supported by robust validation, spike recovery studies, and method comparability assessments. As endotoxin control becomes more critical in advanced therapeutics, standardized validation tools such as Endotoxin Challenge Vials (ECVs) are playing an increasingly important role in depyrogenation validation and process qualification. The future of endotoxin testing is not about replacement—it is about method diversification, regulatory alignment, and stronger validation science. #EndotoxinTesting #USP85 #USP86 #PharmaceuticalQC #Validation #Biologics #CellTherapy #GeneTherapy #GMP #QualityControl #RecombinantProteins #LALAssay #TALReagent #PharmaIndustry